Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutations

CONTEXT: Pregnancy and puerperium raise the risk of thromboembolic events, and these risks are increased in women who are carriers of thrombophilia factors. Prothrombin (FII) G20210A and factor V Leiden heterozygous mutations are associated with moderate risk of thrombosis. The association of these...

Full description

Bibliographic Details
Main Authors: Egle Couto, Marcelo Luís Nomura, Ricardo Barini, João Luiz Pinto e Silva
Format: Article
Language:English
Published: Associação Paulista de Medicina
Series:São Paulo Medical Journal
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000600007&lng=en&tlng=en
_version_ 1819205809774526464
author Egle Couto
Marcelo Luís Nomura
Ricardo Barini
João Luiz Pinto e Silva
author_facet Egle Couto
Marcelo Luís Nomura
Ricardo Barini
João Luiz Pinto e Silva
author_sort Egle Couto
collection DOAJ
description CONTEXT: Pregnancy and puerperium raise the risk of thromboembolic events, and these risks are increased in women who are carriers of thrombophilia factors. Prothrombin (FII) G20210A and factor V Leiden heterozygous mutations are associated with moderate risk of thrombosis. The association of these thrombophilic conditions is very rare in pregnancy, and the real risk of thrombosis is unknown. CASE REPORT: We describe a case of a pregnant woman who was found to be carrier of heterozygous factor V Leiden and prothrombin (FII) G20210A mutations. Five years before pregnancy she had had an episode of extensive deep venous thrombosis in the ileofemoral region, while using hormonal contraceptives. Anticardiolipin antibody (ACA), lupus anticoagulant and deficiencies of protein C, protein S and antithrombin III were evaluated by means of enzyme-linked immunosorbent assay (ELISA), dilute Russell Viper Venom time (dRVVT), coagulometric and chromogenic methods. Deoxyribonucleic acid (DNA) was amplified using the polymerase chain reaction (PCR) to study the factor V Leiden and G20210A mutations in the prothrombin gene and C677T mutation in the methylene tetrahydrofolate reductase (MTHFR) gene. In the sixth week of her first pregnancy, she developed another episode of deep venous thrombosis in the femoropopliteal veins of the right leg. She was treated with low-molecular weight heparin (nadroparin) until parturition (0.3 ml or 2,850 UI/day). The pregnancy evolved without any significant obstetric morbidity. The patient delivered a healthy baby by cesarean section. During the puerperium, she used prophylactic doses of nadroparin for (0.3 ml or 2,850 UI/day) six weeks and had no complications. We suggest that women who have an association of thrombophilia factors and a prior episode of venous thromboembolism must have antepartum anticoagulation management using unfractioned or low-molecular weight heparin and postpartum management using low-molecular weight heparin or oral anticoagulants. Anticoagulation is recommended during pregnancy because the real magnitude of the risk of major and life-threatening thromboembolic events in these women is unknown.
first_indexed 2024-12-23T04:57:37Z
format Article
id doaj.art-7d8bc2b0104943aca1c9602d52e2bb13
institution Directory Open Access Journal
issn 1806-9460
language English
last_indexed 2024-12-23T04:57:37Z
publisher Associação Paulista de Medicina
record_format Article
series São Paulo Medical Journal
spelling doaj.art-7d8bc2b0104943aca1c9602d52e2bb132022-12-21T17:59:18ZengAssociação Paulista de MedicinaSão Paulo Medical Journal1806-9460123628628810.1590/S1516-31802005000600007S1516-31802005000600007Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutationsEgle Couto0Marcelo Luís Nomura1Ricardo Barini2João Luiz Pinto e Silva3Universidade Estadual de CampinasUniversidade Estadual de CampinasUniversidade Estadual de CampinasUniversidade Estadual de CampinasCONTEXT: Pregnancy and puerperium raise the risk of thromboembolic events, and these risks are increased in women who are carriers of thrombophilia factors. Prothrombin (FII) G20210A and factor V Leiden heterozygous mutations are associated with moderate risk of thrombosis. The association of these thrombophilic conditions is very rare in pregnancy, and the real risk of thrombosis is unknown. CASE REPORT: We describe a case of a pregnant woman who was found to be carrier of heterozygous factor V Leiden and prothrombin (FII) G20210A mutations. Five years before pregnancy she had had an episode of extensive deep venous thrombosis in the ileofemoral region, while using hormonal contraceptives. Anticardiolipin antibody (ACA), lupus anticoagulant and deficiencies of protein C, protein S and antithrombin III were evaluated by means of enzyme-linked immunosorbent assay (ELISA), dilute Russell Viper Venom time (dRVVT), coagulometric and chromogenic methods. Deoxyribonucleic acid (DNA) was amplified using the polymerase chain reaction (PCR) to study the factor V Leiden and G20210A mutations in the prothrombin gene and C677T mutation in the methylene tetrahydrofolate reductase (MTHFR) gene. In the sixth week of her first pregnancy, she developed another episode of deep venous thrombosis in the femoropopliteal veins of the right leg. She was treated with low-molecular weight heparin (nadroparin) until parturition (0.3 ml or 2,850 UI/day). The pregnancy evolved without any significant obstetric morbidity. The patient delivered a healthy baby by cesarean section. During the puerperium, she used prophylactic doses of nadroparin for (0.3 ml or 2,850 UI/day) six weeks and had no complications. We suggest that women who have an association of thrombophilia factors and a prior episode of venous thromboembolism must have antepartum anticoagulation management using unfractioned or low-molecular weight heparin and postpartum management using low-molecular weight heparin or oral anticoagulants. Anticoagulation is recommended during pregnancy because the real magnitude of the risk of major and life-threatening thromboembolic events in these women is unknown.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000600007&lng=en&tlng=enPregnancyThromboembolismThrombophiliaThrombosisFactor V
spellingShingle Egle Couto
Marcelo Luís Nomura
Ricardo Barini
João Luiz Pinto e Silva
Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutations
São Paulo Medical Journal
Pregnancy
Thromboembolism
Thrombophilia
Thrombosis
Factor V
title Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutations
title_full Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutations
title_fullStr Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutations
title_full_unstemmed Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutations
title_short Pregnancy-associated venous thromboembolism in combined heterozygous factor V Leiden and prothrombin G20210A mutations
title_sort pregnancy associated venous thromboembolism in combined heterozygous factor v leiden and prothrombin g20210a mutations
topic Pregnancy
Thromboembolism
Thrombophilia
Thrombosis
Factor V
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-31802005000600007&lng=en&tlng=en
work_keys_str_mv AT eglecouto pregnancyassociatedvenousthromboembolismincombinedheterozygousfactorvleidenandprothrombing20210amutations
AT marceloluisnomura pregnancyassociatedvenousthromboembolismincombinedheterozygousfactorvleidenandprothrombing20210amutations
AT ricardobarini pregnancyassociatedvenousthromboembolismincombinedheterozygousfactorvleidenandprothrombing20210amutations
AT joaoluizpintoesilva pregnancyassociatedvenousthromboembolismincombinedheterozygousfactorvleidenandprothrombing20210amutations